"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...
By integrating NVIDIA’s digital twins, foundation models, and perception AI, Multiply Labs is pioneering a new era of robotic ...
New York, United States, January 7th, 2026, FinanceWireGlobal investment management leader Aurum Capital has announced the ...
Zacks.com on MSN
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions ...
Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for ...
Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal ...
LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback